2,3-Dihydrobenzofuran CAS 496-16-2 Ramelteon Intermediate Purity >99.0% (GC)

2,3-Dihydrobenzofuran (CAS: 496-16-2) is widely used in the synthesis of tricyclic compounds and is also an intermediate raw material for the synthesis of some important drugs. 2,3-Dihydrobenzofuran can be used as an intermediate of Ramelteon (CAS: 196597-26-9). Ramelteon, marketed as Rozerem by Takeda Pharmaceuticals North America, is a sleep agent that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABAA receptors, such as with drugs like zolpidem. It however does not appear to speed the onset of sleep or the amount of sleep a person gets. It is approved by the U.S. Food and Drug Administration (FDA) for long-term use. Ramelteon does not show any appreciable binding to GABAA receptors, which are associated with anxiolytic, myorelaxant, and amnesic effects. Unlike most treatments of insomnia that target the GABA (g-aminobutyric acid) receptor complex, ramelteon is an agonist of the melatonin receptor. In particular, it has high selectivity for the MT1 and MT2 subtypes, which have been implicated in the maintenance of circadian rhythms, over the MT3 receptor responsible for other melatonin functions. 2,3-Dihydrobenzofuran is also used in the synthesis of antitumor agents benzofuran sulfonylureas, HIV protease inhibitor amino acid hydroxyethylenesulfonyl, matrix metalloproteinase inhibitor aryl sulfinyl isoxime hydroxamic acid, etc.